ENvue Medical, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.6M | $2.6M | $2.3M | $752,000 | $1.7M |
| Cost of revenue | $2.4M | $1.1M | $746,000 | $585,000 | $925,000 |
| Gross profit | $153,000 | $1.5M | $1.5M | $167,000 | $770,000 |
| Research and development | $1.8M | $909,000 | $185,000 | $283,000 | $293,000 |
| Operating expenses | $23.0M | $5.1M | $5.0M | $5.2M | $6.5M |
| Operating income | -$22.9M | -$3.6M | -$3.4M | -$5.0M | -$5.7M |
| Interest expense | — | $135,000 | $135,000 | $347,000 | — |
| Pretax income | -$18.5M | -$3.7M | -$3.7M | -$5.4M | -$14.2M |
| Income tax expense | -$307,000 | $19,000 | $29,000 | $35,000 | $32,000 |
| Net income | -$18.2M | -$3.7M | -$3.7M | -$5.4M | -$14.3M |
| Balance Sheet | |||||
| Cash and equivalents | $4.2M | $752,000 | — | — | $7.7M |
| Current assets | $7.3M | $3.3M | $6.5M | $5.6M | $8.3M |
| Total assets | $41.1M | $3.6M | $6.7M | $5.9M | $8.6M |
| Current liabilities | $6.7M | $2.7M | $2.5M | $2.3M | $1.9M |
| Total liabilities | $7.6M | $3.0M | $2.7M | $2.6M | $2.3M |
| Stockholders' equity | $33.5M | $627,000 | $4.0M | $3.2M | $6.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$9.4M | -$2.5M | -$3.6M | -$7.0M | -$4.4M |
| Depreciation and amortization | $897,000 | $1,000 | $1,000 | $1,000 | $2,000 |
| Stock-based compensation | — | $356,000 | $293,000 | $354,000 | $382,000 |
| Capital expenditure | $60,000 | $3,000 | $1,000 | $3,000 | $3,000 |
| Free cash flow | -$9.4M | -$2.5M | -$3.6M | -$7.0M | -$4.4M |
| Share repurchases | $5.0M | — | — | — | — |
| Impairments | $11.2M | $0 | — | — | — |
Shares outstanding 6.1M · Free float 96.1%
Annual filing data through FY ended December 31, 2025; float as of July 12, 2026.